Think of Leqvio as a Niche Med for Lowering LDL
December 2022
Rx Leqvio (inclisiran) will be the first “small interfering RNA” (siRNA) therapy for lowering cholesterol.
This injectable works at a different step in the same pathway as the PCSK9 inhibitors, Praluent (alirocumab) and Repatha (evolocumab).
Leqvio prevents formation of the PCSK9 protein...Praluent and Repatha prevent PCSK9 binding. All of them increase LDL receptors in the liver and clear LDL cholesterol from the blood.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive